Our commitment to collaboration extends to every aspect of our oncology work–from research and development to clinical trials, from product availability to patient education.
Our internal research efforts are balanced with external collaborations across the highest levels of industry, academia and government. It is this intense focus on collaboration to bring together the best and smartest minds in oncology that will help us outsmart cancer.
Some of our partners include:
AbbVie and Genentech pioneered BCL-2 research with the joint development of venetoclax. AbbVie and Genentech continue to partner in investigating venetoclax in chronic lymphocytic leukemia and other hematologic cancers and conditions.
AbbVie and The University of Texas’ MD Anderson Cancer Center have joined forces to find new ways to unleash the immune system’s potential to fight cancer. The three-year collaboration is focused on creating efficiencies in preclinical and clinical studies to advance the field of immuno-oncology.
AbbVie and Bristol-Myers Squibb jointly developed elotuzumab. In addition to the approved indication in multiple myeloma, AbbVie and BMS have ongoing clinical trials for other assets and types of cancer.
See the additional companies we collaborate with below.